{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:19:37Z","timestamp":1788981577777,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01017-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:04:22Z","timestamp":1782234262000},"page":"475-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Relevance of the 516 G>T Polymorphism in CYP2B6 and Its Effects on Efavirenz Concentrations in Patients with HIV and Tuberculosis: A Meta-analysis"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1279-3517","authenticated-orcid":false,"given":"Alexandra","family":"Villalpando-Sol\u00f3rzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6113-5623","authenticated-orcid":false,"given":"Ashley Marieth","family":"Ramirez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6172-3314","authenticated-orcid":false,"given":"Jos\u00e9 Giovanni","family":"Navarro-Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2387-9471","authenticated-orcid":false,"given":"Yair","family":"Lara-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-4075","authenticated-orcid":false,"given":"Genaro","family":"Rodr\u00edguez-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0445-7601","authenticated-orcid":false,"given":"Jos\u00e9 Rom\u00e1n","family":"Chavez-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1017_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","volume":"9","author":"L-G Bekker","year":"2023","unstructured":"Bekker L-G, Beyrer C, Mgodi N, Lewin SR, Delany-Moretlwe S, Taiwo B, et al. HIV infection. Nat Rev Dis Primer. 2023;9:42. https:\/\/doi.org\/10.1038\/s41572-023-00452-3.","journal-title":"Nat Rev Dis Primer"},{"key":"1017_CR2","unstructured":"-Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2025. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"1017_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496\u2013526.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1017_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ijantimicag.2013.10.022","volume":"43","author":"W Manosuthi","year":"2014","unstructured":"Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, et al. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy. Int J Antimicrob Agents. 2014;43(3):292\u20136. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.10.022.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1017_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563\u201372.","journal-title":"Clin Pharmacol Ther"},{"key":"1017_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040180","volume":"7","author":"S Mugusi","year":"2012","unstructured":"Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS ONE. 2012;7:e40180. https:\/\/doi.org\/10.1371\/journal.pone.0040180.","journal-title":"PLoS ONE"},{"key":"1017_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMra2308181","volume":"391","author":"G Meintjes","year":"2024","unstructured":"Meintjes G, Maartens G. HIV-Associated Tuberculosis. N Engl J Med. 2024;391:343\u201355. https:\/\/doi.org\/10.1056\/NEJMra2308181.","journal-title":"N Engl J Med"},{"key":"1017_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/09564624221134137","volume":"34","author":"L Zhang","year":"2022","unstructured":"Zhang L, Meng X, Dong P, Qi T, Liu L, Wang B. Effects of Rifampicin, CYP2B6 and ABCB1 polymorphisms on efavirenz plasma concentration in Chinese patients living with HIV and tuberculosis. Int J STD AIDS. 2022;34:37\u201347. https:\/\/doi.org\/10.1177\/09564624221134137.","journal-title":"Int J STD AIDS"},{"issue":"12","key":"1017_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027810","volume":"6","author":"G Yimer","year":"2011","unstructured":"Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and Rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE. 2011;6(12):e27810. https:\/\/doi.org\/10.1371\/journal.pone.0027810.","journal-title":"PLoS ONE"},{"key":"1017_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-6405-7-32","volume":"7","author":"V Gounden","year":"2010","unstructured":"Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G>T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther. 2010;7:32.","journal-title":"AIDS Res Ther"},{"key":"1017_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:1\u20139. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1017_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan: a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1017_CR13","unstructured":"-The Cochrane Collaboration. RevMan\u2014systematic review and meta-analysis tool for researchers worldwide. https:\/\/revman.cochrane.org\/info"},{"key":"1017_CR14","unstructured":"-Corporation for Digital Scholarship. Zotero [reference management software]. https:\/\/www.zotero.org"},{"key":"1017_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky379","author":"A Von Braun","year":"2019","unstructured":"Von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, et al. High efavirenz serum concentrations in TB\/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. J Antimicrob Chemother. 2019. https:\/\/doi.org\/10.1093\/jac\/dky379.","journal-title":"J Antimicrob Chemother"},{"key":"1017_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3851\/IMP2877","volume":"20","author":"TN Gengiah","year":"2014","unstructured":"Gengiah TN, Botha JH, Yende-Zuma N, Naidoo K, Karim SSA. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment. Antivir Ther. 2014;20:297\u2013306. https:\/\/doi.org\/10.3851\/IMP2877.","journal-title":"Antivir Ther"},{"key":"1017_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.antiviral.2013.11.011","volume":"102","author":"E Bienvenu","year":"2014","unstructured":"Bienvenu E, Swart M, Dandara C, Ashton M. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Antiviral Res. 2014;102:44\u201353. https:\/\/doi.org\/10.1016\/j.antiviral.2013.11.011.","journal-title":"Antiviral Res"},{"key":"1017_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-7-8","author":"S Uttayamakul","year":"2010","unstructured":"Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with Rifampicin in HIV\/TB co-infected Thai adults. AIDS Res Ther. 2010. https:\/\/doi.org\/10.1186\/1742-6405-7-8.","journal-title":"AIDS Res Ther"},{"key":"1017_CR19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1177\/0091270008321790","volume":"48","author":"A Kwara","year":"2008","unstructured":"Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, et al. Pharmacokinetics of efavirenz when co-administered with Rifampin in TB\/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol. 2008;48:1032\u201340. https:\/\/doi.org\/10.1177\/0091270008321790.","journal-title":"J Clin Pharmacol"},{"key":"1017_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1017_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"4","key":"1017_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1124\/pharmrev.122.000810","volume":"75","author":"W Sadee","year":"2023","unstructured":"Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: driving personalized medicine. Pharmacol Rev. 2023;75(4):789\u2013814. https:\/\/doi.org\/10.1124\/pharmrev.122.000810.","journal-title":"Pharmacol Rev"},{"issue":"24","key":"1017_CR23","doi-asserted-by":"publisher","first-page":"00003","DOI":"10.1016\/j.farma.2023.12.004","volume":"S1130\u20136343","author":"L Amaro-\u00c1lvarez","year":"2024","unstructured":"Amaro-\u00c1lvarez L, Cordero-Ramos J, Calleja-Hern\u00e1ndez M\u00c1. Exploring the impact of pharmacogenetics on personalized medicine: a systematic review. Farm Hosp. 2024;S1130\u20136343(24):00003\u20135. https:\/\/doi.org\/10.1016\/j.farma.2023.12.004.","journal-title":"Farm Hosp"},{"key":"1017_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79965-0","author":"N Chanhom","year":"2024","unstructured":"Chanhom N, Sonjan J, Inchai J, Udomsinprasert W, Chaikledkaew U, Suvichapanich S, et al. Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-024-79965-0.","journal-title":"Sci Rep"},{"key":"1017_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/cpt.2327","volume":"110","author":"JA Luzum","year":"2021","unstructured":"Luzum JA, Petry N, Taylor AK, Van Driest SL, Dunnenberger HM, Cavallari LH. Moving pharmacogenetics into practice: it\u2019s all about the evidence! Clin Pharmacol Ther. 2021;110:649\u201361. https:\/\/doi.org\/10.1002\/cpt.2327.","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01017-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01017-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01017-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:21Z","timestamp":1788980181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01017-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01017-x","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a secondary analysis of previously published data. All included primary studies reported approval from their respective ethics committees or institutional review boards. No new data collection involving human participants was conducted; therefore, additional ethical approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}